Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Interest & Investment Income (2016 - 2019)

Tg Therapeutics has reported Interest & Investment Income over the past 4 years, most recently at $1.1 million for Q2 2019.

  • Quarterly results put Interest & Investment Income at $1.1 million for Q2 2019, up 382.96% from a year ago — trailing twelve months through Jun 2019 was $1.8 million (up 208.64% YoY), and the annual figure for FY2018 was $857000.0, up 190.51%.
  • Interest & Investment Income for Q2 2019 was $1.1 million at Tg Therapeutics, up from $149000.0 in the prior quarter.
  • Over the last five years, Interest & Investment Income for TGTX hit a ceiling of $1.1 million in Q2 2019 and a floor of $45000.0 in Q1 2017.
  • Median Interest & Investment Income over the past 4 years was $106814.5 (2016), compared with a mean of $195357.1.
  • Biggest five-year swings in Interest & Investment Income: plummeted 46.97% in 2017 and later surged 382.96% in 2019.
  • Tg Therapeutics' Interest & Investment Income stood at $57544.0 in 2016, then skyrocketed by 110.27% to $121000.0 in 2017, then skyrocketed by 119.83% to $266000.0 in 2018, then soared by 304.89% to $1.1 million in 2019.
  • The last three reported values for Interest & Investment Income were $1.1 million (Q2 2019), $149000.0 (Q1 2019), and $266000.0 (Q4 2018) per Business Quant data.